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Objective: Limited evidence exists on the use of corticosteroids 
in pediatric shock. We sought to determine physicians’ practices 
and beliefs with regard to the management of pediatric shock.
Design: Cross-sectional, Internet-based survey.
Setting: Canada.
Subjects: Physicians identified as practicing pediatric intensive 
care in any of 15 academic centers.
Measurements and Main Results: Seventy of 97 physicians 
(72.2%) responded. Physicians stated that they were more likely 
to prescribe steroids for septic shock than for shock following 
cardiac surgery (odds ratio, 1.9 [95% CI, 0.9–4.3]) or trauma 
(odds ratio, 11.46 [95% CI, 2.5–51.2]), and 91.4% (64/70) 
would administer steroids to patients who had received 60 cc/
kg of fluid and two or more vasoactive medications. Thirty-five 
percent of respondents (25/70) reported that they rarely or 
never conducted adrenal axis testing before giving steroids to 
patients in shock. Eighty-seven percent of respondents (61/70) 
stated that the role of steroids in the treatment of fluid and/or 
vasoactive drug-dependent shock needed to be clarified and that 
84.3% would be willing to randomize patients into a trial of ste-
roid efficacy who were fluid resuscitated and on one high-dose 
vasoactive medication. However, 74.3% stated that they would 
start open-label steroids in patients who required two high-dose 
vasoactive medications.
Conclusions:  This survey provides information on the stated beliefs 
and practices of pediatric critical care physicians with regard to 
the use of steroids in fluid and/or vasoactive drug-dependent 
shock. Clinicians feel that the role of steroids in shock still requires 
clarification and that they would be willing to randomize patients 
into a trial. This survey may be useful as an initial framework for 
the development of a future trial on the use of steroids in pediatric 
shock. (Pediatr Crit Care Med 2013; 14:462–466)
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Approximately 2,000 children per year in Canada develop clinical signs of shock requiring life-saving treatments in emergency departments and ICUs. The initial aim 
of shock management is to improve end-organ perfusion 
through IV fluid resuscitation followed by vasoactive medica-
tions. When shock states persist despite significant fluid and/or 
vasoactive infusions, steroids have been suggested as adjunc-
tive therapy (1). The scientific rationale for steroids in refrac-
tory shock is compelling and has been widely debated in both 
the adult and pediatric literature for over 40 years. Recent large 
adult-based randomized controlled trials have provided con-
flicting answers with some suggesting more harm than benefit 
(2, 3). No sufficiently powered trials have evaluated steroids in 
the treatment of pediatric shock.
Developing evidence-based guidelines for pediatric shock 
management has proven difficult given the conflicting adult 
evidence and the absence of pediatric trials. A large retrospective 
A Survey of Stated Physician Practices and Beliefs 
on the Use of Steroids in Pediatric Fluid and/or 
Vasoactive Infusion-Dependent Shock*
Kusum Menon, MD, MSc, FRCPC1; James D. McNally, MD, PhD, FRCPC1;  
Karen Choong, MB, MSc, FRCPC2; Roxanne E. Ward, BA3; Margaret L. Lawson, MD, MSc, FRCPC1; 
Tim Ramsay, MSc, PhD4; Hector R. Wong, MD5
*See also p. 541.
1Department of Pediatrics, Children’s Hospital of Eastern Ontario, Univer-
sity of Ottawa, Ottawa, ON, Canada.
2Department of Pediatrics, McMaster University, Ottawa, ON, Canada.
3Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, 
Canada.
4Department of Epidemiology and Community Medicine, Ottawa Hospital 
Research Institute, University of Ottawa, Ottawa, ON, Canada.
5Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, 
University of Cincinnati College of Medicine, Cincinnati, OH.
This work was performed at the Children’s Hospital of Eastern Ontario.
Dr. McNally is an academic pediatric intensivist paid to provide clinical 
service and engage in scholarly activity, including research. Dr. Choong 
received grant support from CIHR. Dr. Ward receives payment for writing 
and reviewing the manuscript/preparation: Children's Hospital of Eastern 
Ontario Research Institute—paid salary for role as Critical Care Clinical 
Research Manager. Dr. Wong receives grant support from NIH and pay-
ment for lectures from SCCM. The remaining  authors have disclosed that 
they do not have any potential conflicts of interest.
For information regarding this article, E-mail: menon@cheo.on.ca
Copyright © 2013 by the Society of Critical Care Medicine and the World 
Federation of Pediatric Intensive and Critical Care Societies
DOI: 10.1097/PCC.0b013e31828a7287
Feature Articles
Pediatric Critical Care Medicine www.pccmjournal.org 463
study of patients with sepsis and the subsequent 2009 update 
of the American College of Critical Care Medicine guidelines 
both maintain equipoise on the question of adjunctive steroid 
therapy for pediatric sepsis (1, 4). The guidelines further 
demonstrate a significant knowledge gap by recommending a 
hydrocortisone dose ranging from 1 to 50 mg/kg/d for children 
with septic shock. Consequently, clinicians providing care to 
these children are left to make individual judgments at the 
bedside, potentially resulting in significant practice variation 
and polarized opinions on the subject (5–7).
An understanding of current physician practices and beliefs is 
essential prior to future interventional trials of steroids in pedi-
atric shock. To date, three studies have assessed the practice of 
pediatric intensive care physicians in the management of patients 
with shock or adrenal insufficiency (5–7). All three demonstrated 
variability in physician practices and beliefs but had significant 
limitations including proxy reporting by medical directors (5), a 
differing/alternative focus (6), or a single-center design (7) pre-
venting broad-based conclusions. Due to limited current evi-
dence on physician practices with regard to the use of steroids in 
shock, it is difficult to determine whether consensus or equipoise 
exists on the management of pediatric shock patients. We there-
fore performed a survey study of pediatric critical care physicians 
in Canada to determine their current practices and beliefs with 
regard to use of corticosteroids in the management of shock and 
their willingness to participate in a future trial on the subject.
METHODS
Sampling Frame
All currently practicing attending pediatric intensivists at the 15 
academic health science centers in Canada were identified as the 
population of interest. We identified potential respondents by 
contacting one pediatric intensivist at each of the study sites who 
was asked to provide the names and e-mail addresses of all the 
physicians currently practicing pediatric critical care in their ICU.
Questionnaire Development
Development of this self-administered questionnaire was accord-
ing to recently published recommendations for survey methodol-
ogy (8). First, we generated relevant items for the questionnaire 
through literature reviews and in-depth interviews with experts 
in the field including members of the Canadian Critical Care Tri-
als Group. The generated items were then grouped into domains 
which primarily included practice patterns and beliefs around 
the use of corticosteroids in pediatric fluid and/or vasoactive 
infusion-dependent shock. A question on the effect of etomi-
date usage on the subsequent use of steroids for shock was not 
included as a previous study in the Canadian pediatric intensive 
population showed that none of the 369 critically ill children had 
received etomidate prior to PICU admission (9).
Questionnaire Testing
The questionnaire was sent to five individuals with method-
ological and/or content expertise in the field who would not 
be respondents for the final version and included pediatric 
intensivists, a pediatric intensive care fellow (an intensivist 
from Brazil), a pediatric endocrinologist, and an experienced 
pediatric critical care research coordinator with training in 
epidemiology. Individual questions were extensively revised 
based on feedback from this group. The questionnaire was 
then sent to five adult intensivists who were asked to examine 
the flow, salience, acceptability, and administrative ease of the 
questionnaire after which further revisions to the content and 
order of the survey were made.
Questionnaire Administration
We administered the survey (see Appendix 1) between February 
and March 2012 in English using web-based software (Fluid-
Surveys; http://www.fluidsurveys.com) and did not provide any 
incentives for completion of the survey. Each potential partici-
pant received an e-mail invitation to complete the survey. Two 
weeks later, a reminder e-mail was sent to those who had not 
completed the survey. A third and final e-mail was sent to poten-
tial participants who had not responded 2 weeks after the second 
reminder. The electronically generated database was then down-
loaded into SPSS version 19, which was then verified by both 
the research coordinator and principal investigator for accuracy.
Statistical Analysis
We summarized survey responses using proportions and 
modes for categorical data, medians for continuous data with 
interquartile ranges (IQR), and odds ratios (OR) with 95% CIs 
for comparisons between proportions. For descriptive analyses, 
we used the actual number of respondents for the denomina-
tor. We collapsed categories, where appropriate to summarize 
responses in a meaningful manner. We included data from 




Ninety-nine pediatric intensive care physicians were eligible 
for the survey and 97 received the survey (two were acciden-
tally omitted). The overall response rate was 72.2% (70/97), 
and the response rates among centers ranged from 53.9% to 
100%. The completion rate of the returned surveys was 97.4%. 
The number of years of clinical practice by physicians in the 
participating units was evenly distributed in 5-year blocks 
from less than 5 years to greater than 20 years (18.6%, 21.4%, 
20.0%, 18.6%, and 21.4%). The number of PICU beds ranged 
from 5–10 to over 20 beds with the most common response 
being 11–20 beds (42.9%). The number of admissions per year 
ranged from less than 200 (2.9%) to greater than 2,000 (4.3%) 
with the majority of units reporting between 600 and 1,000 
(44.3%). The median number of practicing intensivists per 
center was 6 (IQR, 4–10).
Definition of Shock and Burden of Problem
Respondents were provided with clinical scenarios and asked 
to identify all cases that they would define as fluid and/or 
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vasoactive drug-dependent shock (Fig. 1). Hypotension despite 
60 cc/kg of fluid was the most common definition chosen 
(37.1%, 26/70) followed by hypotension despite 60 cc/kg of 
fluid and one low-dose vasoactive infusion (30.0%, 21/70).
Respondents were asked to provide an estimate of the 
overall prevalence of patients with moderate-to-severe shock 
treated at their center (defined in this instance as hypotension 
despite 60 cc/kg of fluid and at least one vasoactive medica-
tion). The majority of centers reported either less than 50 or 
50–100 admissions for shock per year (mode of the estimates 
in 7/15 and 6/15 centers, respectively) and only one center 
estimated over 200 annual admissions. Ninety-one percent of 
respondents’ estimates (64/70) of the number of shock patients 
were the same or within one category of the mode from their 
institution.
Practice Patterns for Steroid Administration in Shock
Physicians stated that they were more likely to prescribe ste-
roids for septic shock than for shock following cardiac surgery 
(OR, 1.9 [95% CI, 0.9–4.3]) or trauma (OR, 11.4 [95% CI, 2.5–
51.2]). However, the majority of clinicians surveyed (74.2%, 
52/70) admitted to using steroids in patients with fluid and/
or vasoactive drug-dependent shock secondary to diagnoses 
other than sepsis.
When asked about their threshold for using steroids in 
patients with shock, 92.9% (65/70) stated they would not 
administer steroids for a patient who had received 60 cc/kg of 
fluid and was only on one low-dose vasoactive medication, but 
91.4% (64/70) stated that would administer steroids to patients 
who had received 60 cc/kg of fluid and were on two or more 
vasoactive medications (Fig. 1).
Eighty percent of respondents (56/70) reported using 
exclusively hydrocortisone as their steroid of choice for fluid/
vasopressor-dependent shock 
with the remaining respon-
dents stating that they would 
use only methylprednisolone 
(8.6%, 6/70), methylpredniso-
lone or hydrocortisone (7.1%, 
5/70), only dexamethasone 
(2.9%, 2/70), or methylpred-
nisolone, hydrocortisone, or 
dexamethasone (1.4%, 1/70). 
No respondents reported 
using fludrocortisone. The 
majority of respondents 
(81.4%, 57/70) reported 
using doses of hydrocortisone 
within a narrow range from 
1 mg/kg/dose (47.1%, 33/70) to 
100 mg/m2/d (14.3%, 15/70) to 
5 mg/kg/d (12.9%, 9/70). Just 
over 1% of clinicians surveyed 
stated that they would use only 
50 mg/m2/d of hydrocortisone. 
Remaining responses included 
4–5 mg/kg load followed by 1 mg/kg q6h (2.9%), 10 mg/kg/dose 
(1.4%), and one reference to guideline dosing.
Respondents were asked to identify all criteria that they 
would use to discontinue steroid therapy. Forty-seven percent 
of responding practitioners (33/70) chose resolution of shock 
alone, 20% (20/70) chose discontinuation of all vasoactive 
infusions alone, and 10% (7/70) chose both criteria. Seventeen 
percent of respondents (12/70) simply identified a time limit 
as their criteria for discontinuation of steroid therapy. Only 
three respondents linked their stated duration of therapy to 
the results of the patient’s adrenal axis testing.
Adrenal Function Testing
Thirty-six percent of respondents (25/70) reported that they 
rarely or never conducted adrenal axis testing before giving 
steroids to patients in shock, whereas 37.1% of respondents 
(26/70) stated that they often or always conducted such testing 
prior to starting steroids. The most frequent type of adrenal 
axis testing reported as being performed was a random cortisol 
level (61.4%) with 50.0% reporting conducting low-dose 
(0.5–1.0 μg) adrenocorticotrophic hormone (ACTH) testing 
(respondents were asked to select all applicable answers).
Stated Beliefs on a Controlled Trial of Steroids
Eighty-seven percent of respondents (61/70) stated that the 
role of steroids in the treatment of fluid and/or vasoactive 
drug-dependent shock needed to be clarified. Forty-six per-
cent stated that they would be willing to randomize patients in 
early shock (patients who have received 60 cc/kg of fluid but 
no vasoactive medications) and 84.3% of them in late shock 
(received 60 cc/kg of fluid and at least one high-dose vaso-
active medication) (Fig. 1). With regard to their colleagues’ 
practice, 44.3% of respondents felt that most or all of their 
Figure 1. The reported use of corticosteroids in shock. Gray bars = stated definition of shock; white bars = 
stated criteria for use of steroids; black bars = stated criteria for willingness to randomize.
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colleagues would be willing to randomize patients into a trial 
of steroid versus placebo in early pediatric shock and 61.4% 
of their colleagues would be willing to randomize patients in 
late shock.
The majority of physicians (74.3%) stated that they would 
not start open-label steroids on a patient who had been ran-
domized into a trial of steroids versus placebo and who had 
received greater than or equal to 60 cc/kg of fluid and was on 
one high-dose vasoactive drug, but 74.3% would start open-
label steroids on a patient who had received greater than or 
equal to 60 cc/kg of fluid and was on two or more vasoactive 
drugs.
The single most clinically significant and feasible pri-
mary outcome measure chosen by respondents for a future 
trial was the time to discontinuation of all vasoactive 
drugs (38.6%, 27/70) with time to hemodynamic stability 
(BP > 5th percentile for age) being the second most com-
mon (22.9%, 16/70). The choices for the single most clini-
cally significant and feasible primary outcome measure for 
a future trial on the use of steroids for persistent shock are 
shown in Figure 2.
DISCUSSION
Our survey provides an assessment of pediatric intensivists’ 
beliefs regarding the role of steroids in the management of chil-
dren with fluid and/or vasoactive infusion-dependent shock. 
Interestingly we found that thresholds for defining, treating, 
and randomizing patients with fluid and/or vasoactive infu-
sion-dependent shock differed. The most common definition 
of shock chosen was hypotension despite 60 cc/kg of fluid; the 
most common point at which clinicians would start steroids 
for shock was hypotension following fluid and two vasoactive 
medications, and the stage of shock at which clinicians were 
most willing to randomize 
patients was if patients were 
hypotensive following fluid 
and one high-dose vasoactive 
medication.
Physician practice regard-
ing the administration of 
steroids by shock etiology 
was also explored. Physicians 
reported administering ste-
roids more commonly in 
septic shock patients than 
in the trauma or postopera-
tive cardiac surgery popula-
tion. This is noteworthy given 
that the pediatric critical care 
literature on adrenal insuf-
ficiency is inconclusive as to 
whether sepsis itself increases 
a patient’s risk for adrenal dys-
function (9, 10) but suggests 
that trauma (9) and cardiac 
surgery (11, 12) patients are at 
risk for adrenal insufficiency. The reasons for this discrepancy 
are unclear but may simply reflect the preponderance of stud-
ies focusing on pediatric septic shock (13–16). There was also 
a significant discrepancy in the endpoints chosen by respon-
dents for discontinuation of steroids, which will need to be 
carefully considered in the design of a future trial.
Multiple studies have shown that random cortisol 
levels alone may be inadequate for the detection of adrenal 
dysfunction (9, 16–18). Despite this literature, the majority of 
those surveyed who reported conducting adrenal axis testing 
(64.8%) stated that they performed random cortisol levels. This 
may be related to difficulties conducting an ACTH stimulation 
test in an acute situation or the lack of clear evidence that 
ACTH stimulation testing is useful in the face of conflicting 
studies on the association of the results of adrenal testing with 
clinically important outcomes (9, 18).
The variation in the reported dose of hydrocortisone that 
clinicians would use for fluid and/or vasoactive drug-depen-
dent shock is consistent with the variability in the published 
literature. The four most recent randomized controlled trials 
(2, 3, 13, 14) used four different dosing regimens, and the 2007 
American College of Critical Care Medicine guidelines for the 
management of pediatric and neonatal shock (1) recommend 
anywhere from 1–2 to 50 mg/kg/d of hydrocortisone for the 
treatment of resistant septic shock.
Finally, our survey explored physicians’ perceptions of 
potential enrollment criteria for a trial on the role of steroids 
in pediatric shock given the varied inclusion criteria use for 
previous randomized controlled trials (2, 3, 14). The major-
ity of respondents stated that they would be willing to enroll 
patients who were still hypotensive despite 60 cc/kg of fluid 
and one high-dose vasoactive medication, and only 24.3% of 
participants stated that they would start open-label steroids 
Figure 2. Clinically significant and feasible outcome measures for a trial on steroids in shock. MODS = multiple 
organ dysfunction syndrome.
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on patients who met the above criteria. However, almost 75% 
of participants would start open-label steroids if their patient 
deteriorated and required two high-dose vasoactive medi-
cations. This suggests that a future trial would likely have to 
enroll patients at an earlier stage of shock to maximize com-
pliance. Deterioration of patients following recruitment at an 
earlier stage of shock could also be a secondary outcome mea-
sure of steroid efficacy.
Two thirds of respondents stated that they would choose 
either time to discontinuation of all vasoactive drugs or time 
to hemodynamic stability as the most clinically significant and 
feasible primary outcomes measures. These outcome measures 
are consistent with pediatric studies that have demonstrated 
significant associations between adrenal insufficiency and time 
on inotropes (16), increased fluid and vasopressor require-
ments (9), and earlier reversal of shock (14). Pediatric stud-
ies on adrenal insufficiency in critical illness have been unable 
to demonstrate an association between adrenal insufficiency 
and mortality (9, 14, 19, 20) due to their small sample sizes 
and the low overall mortality rate in pediatric ICUs (21). This 
is reflected in our survey in which only 5.7% of respondents 
identified mortality as the most clinically significant and fea-
sible outcome measure.
Strengths of this study are that it is a national survey that 
included all 15 level 3 pediatric ICUs in Canada and addresses 
physician beliefs regarding a future randomized controlled 
trial on the use of steroids in pediatric shock. A limitation of 
this study is that it reflects stated rather than actual physician 
practices, and future observational studies on actual steroid 
usage patterns may add valuable extra information. In addi-
tion, our results may not be generalizable outside of Canada 
due to the inclusion of only Canadian sites.
This survey provides information on the stated beliefs and 
practices of pediatric critical care physicians with regard to the 
use of steroids in fluid and/or vasoactive drug-dependent shock. 
Furthermore, our data suggest that the majority of physicians 
surveyed would be willing to randomize patients into a trial. This 
survey provides information that could serve as a basis for the 
development of inclusion criteria and primary outcome mea-
sures for a future trial on the use of steroids in pediatric shock.
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